Çocuk ve Ergenlerde Duygudurum Düzenleyiciler
Özet
Bipolar bozukluk, mani, hipomani ve depresif ataklarla seyreden ömür boyu süren yeti yitimi riskli bir durumdur. Tedavide yaygın olarak kullanılan duygudurum düzenleyiciler (lityum, karbamazepin, lamotrijin ve valproat), etkinliklerinin yanı sıra çocuk ve ergen yaş gruplarında sınırlı çalışmalara sahiptir. Lityum, bipolar bozukluğun koruyucu ve akut mani tedavisinde altın standart olarak kabul edilmekle birlikte, dar terapötik penceresi nedeniyle periyodik plazma konsantrasyonu takibi ve böbrek/tiroid fonksiyon testleri gerektirmektedir. Karbamazepin, akut manik ve karma ataklarda FDA onaylıdır ancak agranülositoz ve ciddi dermatolojik reaksiyon (SJS, TEN) riskleri taşır. Lamotrijin, bipolar depresyonun idame tedavisinde nüksleri önlemede etkili olup hayatı tehdit eden cilt döküntüleri (SJS/TEN) yönünden yakın klinik izlem gerektirir. Valproat ise akut mani tedavisinde yaygın bir antiepileptik ajan olmasına rağmen hepatotoksisite, trombositopeni ve kilo alımı gibi yan etkilere yol açabilir; ayrıca teratojenik riskleri sebebiyle çocuk doğurma çağındaki kadınlarda kullanımı sınırlıdır. Ergenlik döneminde tedaviye uyum oranının %40’ın altında olması ve ilaçların yan etki profillerinin değişkenliği, klinisyenlerin kanıta dayalı ve hastaya özgü stratejiler geliştirmesini, güçlü bir terapötik ittifak kurmasını zorunlu kılmaktadır.
Bipolar disorder is a lifelong, disabling condition characterized by manic, hypomanic, and depressive episodes. Mood stabilizers commonly used in its management (lithium, carbamazepine, lamotrigine, and valproate) have limited research regarding children and adolescents despite their widespread use. Lithium remains the gold standard for maintenance and acute mania treatment, yet its narrow therapeutic window necessitates periodic plasma level monitoring alongside renal and thyroid function tests. Carbamazepine is FDA-approved for acute manic and mixed episodes, but it poses risks of agranulocytosis and severe dermatological reactions like SJS or TEN. Lamotrigine is effective in preventing relapses during the maintenance phase of bipolar depression, though it requires close clinical observation for life-threatening skin rashes. Valproate, an antiepileptic drug widely utilized for acute mania, can induce adverse effects including hepatotoxicity, thrombocytopenia, and weight gain, and its prescription is restricted in females of childbearing potential due to teratogenic risks. Given that treatment adherence drops below 40% in adolescents and side effect profiles vary significantly, clinicians must formulate evidence-based, patient-specific strategies while establishing a robust therapeutic alliance to optimize patient outcomes.
Referanslar
J M, R K, RL F. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107-125. doi:10.1097/01.CHI.0000242240.69678.C4
Machado-Vieira R, Henter I, Zarate CA, Manji HK. Mood Stabilizers. Curated Ref Collect Neurosci Biobehav Psychol. Published online April 28, 2022:967-974. doi:10.1016/B978-0-12-809324-5.02127-1
Mccormick U, Murray B, Mcnew B. Diagnosis and treatment of patients with bipolar disorder: A review for advanced practice nurses. J Am Assoc Nurse Pract. 2015;27(9):530. doi:10.1002/2327-6924.12275
Munch G, Godart N. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review]. Encephale. 2017;43(5):464-470. doi:10.1016/J.ENCEP.2016.09.005
Fda. Tegretol ® carbamazepine USP Chewable Tablets of 100 mg-red-speckled, pink Tablets of 200 mg-pink.
Fricke-Galindo I, LLerena A, Jung-Cook H, López-López M. Carbamazepine adverse drug reactions. Expert Rev Clin Pharmacol. 2018;11(7):705-718. doi:10.1080/17512433.2018.1486707
Borrelli EP, Lee EY, Descoteaux AM, Kogut SJ, Caffrey AR. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System. Epilepsia. 2018;59(12):2318-2324. doi:10.1111/EPI.14591
de Miranda AS, de Miranda AS, Teixeira AL. Lamotrigine as a mood stabilizer: insights from the pre-clinical evidence. Expert Opin Drug Discov. 2019;14(2):179-190. doi:10.1080/17460441.2019.1553951
Lamictal | European Medicines Agency. Accessed September 10, 2022. https://www.ema.europa.eu/en/medicines/human/referrals/lamictal
Naguy A, Al-Enezi N. Lamotrigine Uses in Psychiatric Practice. Am J Ther. 2019;26(1):e96-e102. doi:10.1097/MJT.0000000000000535
Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry. 2010;196(1):4-12. doi:10.1192/BJP.BP.108.062984
Stahl SM. Prescriber’s Guide: Essential Psychopharmacology (6th Ed.).; 2017.
Bipolar disorder: assessment and management Clinical guideline. Published online 2014. Accessed October 5, 2022. www.nice.org.uk/guidance/cg185
GlaxoSmithKline. Lamictal (lamotrigine) tablets, chewable dispersible tablets, and orally disintegrating tablets prescribing information. Research Triangle Park, NC; 2009 Sep.
Tondo L, Alda M, Bauer M, et al. Clinical use of lithium salts: guide for users and prescribers. Int J Bipolar Disord. 2019;7:16. doi:10.1186/s40345-019-0151-2
Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003;290(11):1467-1473. doi:10.1001/JAMA.290.11.1467
Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008;22(4):343-396. doi:10.1177/0269881107088441
Malhi GS, Gershon S, Outhred T. Lithiumeter: Version 2.0. Bipolar Disord. 2016;18(8):631-641. doi:10.1111/BDI.12455
Pérez de Mendiola X, Hidalgo-Mazzei D, Vieta E, González-Pinto A. Overview of lithium’s use: a nationwide survey. Int J Bipolar Disord. 2021;9(1):1-8. doi:10.1186/S40345-020-00215-Z/FIGURES/2
Chronicle EP, Mulleners WM. Anticonvulsant drugs for migraine prophylaxis. Cochrane database Syst Rev. 2004;2004(3). doi:10.1002/14651858.CD003226.PUB2
Fda. HIGHLIGHTS OF PRESCRIBING INFORMATION See 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Published online 2011. Accessed October 6, 2022. www.fda.gov/medwatch
Valproate | European Medicines Agency. Accessed October 6, 2022. https://www.ema.europa.eu/en/medicines/human/referrals/valproate
Hirschfeld RMA, Clayton PJ, Cohen I, et al. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry. 1994;151(12 Suppl):1-36. doi:10.1176/AJP.151.12.1
Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. Ann Clin Psychiatry. 2000;12(1):35-42. doi:10.1023/A:1009074926921
Buoli M, Serati M, Botturi A, Altamura AC. The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data. Drugs R D. 2018;18(1):1-5. doi:10.1007/S40268-017-0224-6
Sheth RD, Wesolowski CA, Jacob JC, et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr. 1995;127(2):256-262. doi:10.1016/S0022-3476(95)70304-7
Bilo L, Meo R. Polycystic ovary syndrome in women using valproate: a review. Gynecol Endocrinol. 2008;24(10):562-570. doi:10.1080/09513590802288259
Orsolini L, Pompili S, Volpe U. The ‘collateral side’ of mood stabilizers: safety and evidence-based strategies for managing side effects. https://doi.org/101080/1474033820201820984. 2020;19(11):1461-1495. doi:10.1080/14740338.2020.1820984
